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background: In a previous analysis, ezetimibe (Eze) given with statin therapy did not increase fasting serum glucose (FSG) levels beyond those 
observed with statins in non-diabetic, hypercholesterolemic (HC) patients over 12 weeks. This analysis evaluated longer-term effects of Eze+ 
simvastatin (Simva).
methods: Mean FSG changes were assessed following Eze + Simva vs Simva treatments in patients who were not on statins at baseline using data 
pooled from 2 randomized, double-blind extension studies in HC patients over 60 weeks, and a study in heterozygous familial hypercholesterolemia 
(heFH) patients over 96 weeks. Individual patient data were analyzed in patients without diabetes at baseline via constrained longitudinal data 
analysis, without multiplicity adjustment. Between treatment differences were calculated.
results: In the HC cohort, mean FSG levels increased similarly with both Simva (N=642) and Eze+Simva (N=695), pooled across doses (10, 20, 
40, 80 mg) (Fig A); the effects were not dose-dependent. FSG increased comparably in the Eze+Simva 80 mg (N=356) and Simva 80 mg (N=348) 
groups in the heFH cohort (Fig B). FSG increases in both cohorts were small (1.6 - 4.6 mg/dL for Simva; 1.0 - 3.7 mg/dL for Eze+Simva) and there 
were no statistically significant differences between the 2 treatments at any timepoint.
conclusion: Consistent with the previous analysis of 12 week data, these data demonstrate that adding Eze to Simva did not impact FSG levels 
any more so than Simva alone when given for up to 96 weeks.
